224 related articles for article (PubMed ID: 24675715)
1. Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease.
Rodríguez-Gallego E; Guirro M; Riera-Borrull M; Hernández-Aguilera A; Mariné-Casadó R; Fernández-Arroyo S; Beltrán-Debón R; Sabench F; Hernández M; del Castillo D; Menendez JA; Camps J; Ras R; Arola L; Joven J
Int J Obes (Lond); 2015 Feb; 39(2):279-87. PubMed ID: 24675715
[TBL] [Abstract][Full Text] [Related]
2. Increased Circulating Levels of Alpha-Ketoglutarate in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Armengol S; Sabench F; Ras R; Hernandez M; Aguilar C; Colom J; Sirvent JJ; Del Castillo D; Richart C
PLoS One; 2016; 11(4):e0154601. PubMed ID: 27123846
[TBL] [Abstract][Full Text] [Related]
3. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
4. Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis.
Cabré N; Luciano-Mateo F; Baiges-Gayà G; Fernández-Arroyo S; Rodríguez-Tomàs E; Hernández-Aguilera A; París M; Sabench F; Del Castillo D; López-Miranda J; Menéndez JA; Camps J; Joven J
Aliment Pharmacol Ther; 2020 Feb; 51(3):374-387. PubMed ID: 31825539
[TBL] [Abstract][Full Text] [Related]
5. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
[TBL] [Abstract][Full Text] [Related]
6. Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review.
Sahebkar A; Sancho E; Abelló D; Camps J; Joven J
J Cell Physiol; 2018 Feb; 233(2):849-855. PubMed ID: 28063221
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive Evaluation of NAFLD with Indocyanine Green Clearance Test: a Preliminary Study in Morbidly Obese Patients Undergoing Bariatric Surgery.
Danin PE; Anty R; Patouraux S; Raucoules-Aimé M; Gugenheim J; Tran A; Gual P; Iannelli A
Obes Surg; 2018 Mar; 28(3):735-742. PubMed ID: 28875438
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.
Barr J; Vázquez-Chantada M; Alonso C; Pérez-Cormenzana M; Mayo R; Galán A; Caballería J; Martín-Duce A; Tran A; Wagner C; Luka Z; Lu SC; Castro A; Le Marchand-Brustel Y; Martínez-Chantar ML; Veyrie N; Clément K; Tordjman J; Gual P; Mato JM
J Proteome Res; 2010 Sep; 9(9):4501-12. PubMed ID: 20684516
[TBL] [Abstract][Full Text] [Related]
9. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach.
Feldman A; Eder SK; Felder TK; Paulweber B; Zandanell S; Stechemesser L; Schranz M; Strebinger G; Huber-Schönauer U; Niederseer D; Patsch W; Weghuber D; Tevini J; Datz C; Aigner E
Diabetes Metab; 2019 Apr; 45(2):132-139. PubMed ID: 30266576
[TBL] [Abstract][Full Text] [Related]
10. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
11. Metabolite profiling can change health-care delivery to obese patients with fatty liver disease: the search for biomarkers.
Camps J; Joven J
Clin Chem Lab Med; 2017 Mar; 55(4):501-506. PubMed ID: 27816954
[TBL] [Abstract][Full Text] [Related]
12. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice.
Tu LN; Showalter MR; Cajka T; Fan S; Pillai VV; Fiehn O; Selvaraj V
Sci Rep; 2017 Jul; 7(1):6120. PubMed ID: 28733574
[TBL] [Abstract][Full Text] [Related]
13. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity.
Jorge ASB; Andrade JMO; Paraíso AF; Jorge GCB; Silveira CM; de Souza LR; Santos EP; Guimaraes ALS; Santos SHS; De-Paula AMB
Obes Res Clin Pract; 2018; 12(Suppl 2):1-8. PubMed ID: 27083404
[TBL] [Abstract][Full Text] [Related]
14. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
[TBL] [Abstract][Full Text] [Related]
15. Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate.
Zwolak A; Szuster-Ciesielska A; Daniluk J; Słabczyńska O; Kandefer-Szerszeń M
PLoS One; 2015; 10(12):e0143851. PubMed ID: 26629827
[TBL] [Abstract][Full Text] [Related]
16. Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population.
Pillai SS; Lakhani HV; Zehra M; Wang J; Dilip A; Puri N; O'Hanlon K; Sodhi K
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933141
[TBL] [Abstract][Full Text] [Related]
17. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome.
Moolla A; de Boer J; Pavlov D; Amin A; Taylor A; Gilligan L; Hughes B; Ryan J; Barnes E; Hassan-Smith Z; Grove J; Aithal GP; Verrijken A; Francque S; Van Gaal L; Armstrong MJ; Newsome PN; Cobbold JF; Arlt W; Biehl M; Tomlinson JW
Aliment Pharmacol Ther; 2020 Jun; 51(11):1188-1197. PubMed ID: 32298002
[TBL] [Abstract][Full Text] [Related]
18. Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.
Arias-Loste MT; Iruzubieta P; Puente Á; Ramos D; Santa Cruz C; Estébanez Á; Llerena S; Alonso-Martín C; San Segundo D; Álvarez L; López Useros A; Fábrega E; López-Hoyos M; Crespo J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834919
[TBL] [Abstract][Full Text] [Related]
19. A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects.
Giraudi PJ; Gambaro SE; Ornelas Arroyo S; Chackelevicius CM; Giuricin M; Silvestri M; Macor D; Crocé LS; Bonazza D; Soardo G; de Manzini N; Zanconati F; Tiribelli C; Palmisano S; Rosso N
Liver Int; 2018 Jan; 38(1):155-163. PubMed ID: 28650518
[TBL] [Abstract][Full Text] [Related]
20. The Potential Biomarkers to Identify the Development of Steatosis in Hyperuricemia.
Tan Y; Liu X; Zhou K; He X; Lu C; He B; Niu X; Xiao C; Xu G; Bian Z; Zu X; Zhang G; Zhang W; Lu A
PLoS One; 2016; 11(2):e0149043. PubMed ID: 26890003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
